| The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox) G Szakács, A Váradi, C Özvegy-Laczka, B Sarkadi Drug discovery today 13 (9-10), 379-393, 2008 | 720 | 2008 |
| High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter C Özvegy-Laczka, T Hegedűs, G Várady, O Ujhelly, JD Schuetz, A Varadi, ... Molecular pharmacology 65 (6), 1485-1495, 2004 | 411 | 2004 |
| ABCG2–a transporter for all seasons B Sarkadi, C Özvegy-Laczka, K Német, A Váradi FEBS letters 567 (1), 116-120, 2004 | 378 | 2004 |
| Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib) NB Elkind, Z Szentpétery, Á Apáti, C Ozvegy-Laczka, G Várady, O Ujhelly, ... Cancer research 65 (5), 1770-1777, 2005 | 284 | 2005 |
| Single nucleotide polymorphisms modify the transporter activity of ABCG2 K Morisaki, RW Robey, C Özvegy-Laczka, Y Honjo, O Polgar, ... Cancer chemotherapy and pharmacology 56, 161-172, 2005 | 274 | 2005 |
| Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties C Hegedűs, C Özvegy‐Laczka, A Apati, M Magocsi, K Nemet, L Őrfi, ... British journal of pharmacology 158 (4), 1153-1164, 2009 | 255 | 2009 |
| Peroxisome proliferator-activated receptor γ-regulated ABCG2 expression confers cytoprotection to human dendritic cells I Szatmari, G Vámosi, P Brazda, BL Balint, S Benko, L Széles, V Jeney, ... Journal of Biological Chemistry 281 (33), 23812-23823, 2006 | 231 | 2006 |
| Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters C Özvegy-Laczka, J Cserepes, NB Elkind, B Sarkadi Drug resistance updates 8 (1-2), 15-26, 2005 | 190 | 2005 |
| Membrane cholesterol selectively modulates the activity of the human ABCG2 multidrug transporter Á Telbisz, M Müller, C Özvegy-Laczka, L Homolya, L Szente, A Váradi, ... Biochimica et Biophysica Acta (BBA)-Biomembranes 1768 (11), 2698-2713, 2007 | 160 | 2007 |
| Functional expression and characterization of the human ABCG1 and ABCG4 proteins: indications for heterodimerization J Cserepes, Z Szentpétery, L Seres, C Özvegy-Laczka, T Langmann, ... Biochemical and biophysical research communications 320 (3), 860-867, 2004 | 141 | 2004 |
| Tyrosine kinase inhibitors as modulators of ATP binding cassette multidrug transporters: substrates, chemosensitizers or inducers of acquired multidrug resistance? A Brózik, C Hegedüs, Z Erdei, T Hegedűs, C Özvegy-Laczka, G Szakács, ... Expert opinion on drug metabolism & toxicology 7 (5), 623-642, 2011 | 132 | 2011 |
| Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface C Ozvegy-Laczka, G Várady, G Köblös, O Ujhelly, J Cervenak, ... Journal of Biological Chemistry 280 (6), 4219-4227, 2005 | 120 | 2005 |
| Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition C Özvegy-Laczka, G Köblös, B Sarkadi, A Váradi Biochimica et Biophysica Acta (BBA)-Biomembranes 1668 (1), 53-63, 2005 | 103 | 2005 |
| The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions D Kovacsics, I Patik, C Özvegy-Laczka Expert opinion on drug metabolism & toxicology 13 (4), 409-424, 2017 | 83 | 2017 |
| Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer … C Hegedüs, K Truta-Feles, G Antalffy, G Várady, K Nemet, ... Biochemical pharmacology 84 (3), 260-267, 2012 | 83 | 2012 |
| Effects of the lipid environment, cholesterol and bile acids on the function of the purified and reconstituted human ABCG2 protein Á Telbisz, C Özvegy-Laczka, T Hegedűs, A Váradi, B Sarkadi Biochemical Journal 450 (2), 387-395, 2013 | 63 | 2013 |
| Interaction of ABC multidrug transporters with anticancer protein kinase inhibitors: substrates and/or inhibitors? C Hegedus, C Ozvegy-Laczka, G Szakacs, B Sarkadi Current Cancer Drug Targets 9 (3), 252-272, 2009 | 60 | 2009 |
| Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter C Ozvegy-Laczka, R Laczkó, C Hegedus, T Litman, G Várady, K Goda, ... Journal of Biological Chemistry 283 (38), 26059-26070, 2008 | 57 | 2008 |
| The role of the human ABCG2 multidrug transporter and its variants in cancer therapy and toxicology J Cervenak, H Andrikovics, C Özvegy-Laczka, A Tordai, K Német, ... Cancer letters 234 (1), 62-72, 2006 | 57 | 2006 |
| Identification of novel cell-impermeant fluorescent substrates for testing the function and drug interaction of Organic Anion-Transporting Polypeptides, OATP1B1/1B3 and 2B1 I Patik, V Székely, O Német, Á Szepesi, N Kucsma, G Várady, G Szakács, ... Scientific reports 8 (1), 2630, 2018 | 54 | 2018 |
